Sonoma Pharmaceuticals, Inc. (SNOA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. on August 19, 2026. The report addresses the outcome of an adjourned special meeting of stockholders originally scheduled to vote on matters outlined in a proxy statement filed on May 5, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting procedures rather than financial performance.
Material Changes and Event Details
- Event: Adjourned Special Meeting of Stockholders held on August 19, 2026.
- Quorum Status: A quorum was not present. The meeting required the presence of 1,157,852 shares (one-third of the 3,473,554 shares entitled to vote as of the April 28, 2026 record date).
- Outcome: The Chairman cancelled the Special Meeting due to the lack of a quorum.
- Future Action: The Company will not solicit additional proxies for this matter.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific business risks. The primary contingency noted is the failure to achieve a quorum, resulting in the cancellation of the vote and the cessation of proxy solicitation.
Key Facts for Investor Verification
- Verify the specific proposals that were intended to be voted on in the cancelled Special Meeting by reviewing the definitive proxy statement filed on May 5, 2026.
- Confirm the total number of shares outstanding and the current record date to understand the voting threshold for any future meetings.
- Monitor subsequent filings to determine if the Company plans to reschedule the vote or abandon the proposed matters.